igella sativa seeds and Febrile Neutropenia
Not Applicable
- Conditions
- Cancerbrain tumors
- Registration Number
- PACTR201503001039326
- Lead Sponsor
- high institute of public health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
children (2-18)years with primary brain tumors.
Exclusion Criteria
1. children with any type of cancer other than brain tumors.
2. children with relapsed brain tumors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of thymoquinone in Nigella sativa seeds may reduce febrile neutropenia risk in pediatric brain tumor patients?
How does Nigella sativa seed administration compare to G-CSF in preventing febrile neutropenia during chemotherapy in pediatric oncology?
Which biomarkers correlate with Nigella sativa efficacy in mitigating chemotherapy-induced neutropenia in brain tumor patients?
What are the safety profiles and adverse event management strategies for Nigella sativa seeds in pediatric cancer treatment?
Are there synergistic effects of combining Nigella sativa seeds with standard chemotherapeutic agents for brain tumor patients at risk of febrile neutropenia?